Filing Flows › Macrogenics (MGNX) › Q1 2025
Macrogenics (MGNX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Macrogenics (MGNX) reported revenue of $13.2M for the first quarter 2025 (Q1 2025), +45% from a year earlier and -32% from the quarter before. Operating margin was -323.1%, net loss $41.0M (311.1% of revenue).
Macrogenics, Q1 2025: revenue $13.2M (+45% year over year), operating margin -323.1%, net loss $41.0M, operating cash flow −$46.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.2M | -32% | +45% |
| Operating profit | −$42.6M | — | — |
| Net earnings | −$41.0M | — | — |
| Operating cash flow | −$46.9M | — | — |
What changed
Revenue was $13.2M in Q1 2025, up 45% year over year and down 32% from the previous quarter. Collaborative and other agreements was the largest line at 53% of revenue. Collaborative and other agreements added $5.4M year over year (up 338%), 133% of the total change.
Operating costs exceeded revenue by $42.6M, an operating margin of -323.1%. Total costs fell 11% while revenue rose 45%. The fastest-growing cost line was Other operating costs (+193%). The quarter ended with a net loss of $41.0M, wider than the previous quarter's $15.4M loss.
Operating cash flow was −$46.9M. Non-cash charges added back $1.8M of depreciation and amortization and $4.4M of share-based compensation. Working capital and other items used $12.0M. Capital expenditures of $529K exceeded it, leaving free cash flow of −$47.4M.
Questions
What was Macrogenics' revenue in the first quarter 2025?
Macrogenics (MGNX) reported revenue of $13.2M for the first quarter 2025 (Q1 2025), +45% from a year earlier and -32% from the quarter before.
Was Macrogenics profitable in the first quarter 2025?
Operating loss was $42.6M (-323.1% of revenue) and net loss $41.0M.
Source: Macrogenics 10-Q on SEC EDGAR.